VeraCyte Secures $28,000,000 Series C Financing Round

  • Feed Type
  • Date
    6/28/2013
  • Company Name
    VeraCyte
  • Mailing Address
    7000 Shoreline Court South San Francisco, CA 94080
  • Company Description
    Veracyte is pioneering the emerging field of molecular cytology. We are developing molecular tests designed to improve the diagnostic accuracy of cytology samples, thereby helping to increase the utility of these minimally invasive procedures as an alternative to surgical biopsy.
  • Website
    http://www.veracyte.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $28,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    This funding will help Veracyte expand availability of our Afirma Thyroid FNA Analysis to help more patients with inconclusive thyroid nodule fine needle aspiration (FNA) biopsy results potentially avoid unnecessary thyroid surgery. This additional capital will also support our investment in research and development of new products similarly designed to help patients avoid unnecessary invasive procedures, while reducing healthcare costs.
  • M&A Terms
  • Venture Investor
    GE Ventures
  • Venture Investor
    Domain Associates
  • Venture Investor
    Kleiner Perkins Caufield & Byers
  • Venture Investor
    TPG Biotech
  • Venture Investor
    Versant Ventures
  • Venture Investor
    jVen Capital

By posting a comment, you agree to our terms and conditions.